CTMX (CytomX Therapeutics) FFO


CTMX CytomX Therapeutics Inc CTMX
36 GF Score
Price $3.32
GF Value $0.28
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CytomX Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

CTMX
36GF Score
CytomX Therapeutics Inc CTMX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CytomX Therapeutics (CTMX) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of $3.32 is trading 1083.9% above its estimated GF Value™ of $0.28. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for CTMX:

  • FFO:
  • GF Value™: $0.28 vs. price of $3.32 (1083.9% above fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CytomX Therapeutics Business Description

Other Exchanges 6C1:Germany
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score

Get the complete analysis for CTMX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.32
Price
$0.28
GF Value